| 回购方案首次披露日 | 2024/9/28 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 | 10 | 月 | 15 | 日~2025 | 年 | 10 | 月 14 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 0万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | | | 累计已回购金额 | 0万元 | | | | | | | | | 实际回购价格区间 | 0元/股~0元/股 | | | | | | | | 一、回购股份的基本情况 公司于 2024 年 9 月 26 日召开第二届董事会第六次临时会议，并于 2024 年 10 月 15 日召开 2024 年第三 ...

今日具体限售解禁股情况如下： 智通财经APP获悉，9月29日共有25家上市公司的限售股解禁，解禁总市值约248.18亿元。 | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 泸州老窖 | 000568 | 股权激励限售流通 | 10.27万 | | 华东医药 | 000963 | 股权激励限售流通 | 21.5万 | | 太原重工 | 600169 | 股权激励限售流通 | 1165.02万 | | 金发科技 | 600143 | 股权激励限售流通 | 740.6万 | | 国泰君安 | 601211 | 股权激励限售流通 | 324.95万 | | 广联达 | 002410 | 股权激励限售流通 | 323.34万 | | 宁波港 | 601018 | 增发A股法人配售上市 | 36.47亿 | | 中金环境 | 300145 | 股权激励限售流通 | 852.07万 | | 可立克 | 002782 | 股权激励限售流通 | 76.8万 | | 英杰电气 | 300820 | 股权激励限售流通 | 6.25万 | | 老百姓 | 6038 ...

9月26日，近岸蛋白涨5.22%，截至发稿，报43.56元/股，成交2360.52万元，换手率1.71%，总市值30.57 亿元。 融通健康产业灵活配置混合A/B（000727）基金经理为万民远。 截至发稿，万民远累计任职时间9年34天，现任基金资产总规模56.29亿元，任职期间最佳基金回报 149.47%， 任职期间最差基金回报-18.43%。 资料显示，苏州近岸蛋白质科技股份有限公司位于江苏省苏州市吴江经济技术开发区云创路228号3层,4 层，成立日期2009年9月7日，上市日期2022年9月29日，公司主营业务涉及靶点及因子类蛋白、重组抗 体、酶及试剂的研发、生产、销售，并提供相关技术服务。主营业务收入构成为：靶点及因子类蛋白 58.04%，酶及试剂25.63%，CRO服务11.87%，重组抗体2.67%，其他(补充)1.79%。 从近岸蛋白十大流通股东角度 数据显示，融通基金旗下1只基金位居近岸蛋白十大流通股东。融通健康产业灵活配置混合A/B （000727）二季度持有股数50万股，持股数量与上期相比不变，占流通股的比例为1.53%。根据测算， 今日浮盈赚取约108万元。 融通健康产业灵活配置混合A/ ...

9月26日，近岸蛋白涨5.22%，截至发稿，报43.56元/股，成交2360.08万元，换手率1.71%，总市值30.57 亿元。 资料显示，苏州近岸蛋白质科技股份有限公司位于江苏省苏州市吴江经济技术开发区云创路228号3层,4 层，成立日期2009年9月7日，上市日期2022年9月29日，公司主营业务涉及靶点及因子类蛋白、重组抗 体、酶及试剂的研发、生产、销售，并提供相关技术服务。主营业务收入构成为：靶点及因子类蛋白 58.04%，酶及试剂25.63%，CRO服务11.87%，重组抗体2.67%，其他(补充)1.79%。 从近岸蛋白十大流通股东角度 数据显示，工银瑞信基金旗下1只基金位居近岸蛋白十大流通股东。工银战略转型股票A（000991）二 季度新进十大流通股东，持有股数33.88万股，占流通股的比例为1.04%。根据测算，今日浮盈赚取约 73.17万元。 工银战略转型股票A（000991）成立日期2015年2月16日，最新规模21.71亿。今年以来收益13.86%，同 类排名3336/4220；近一年收益28.15%，同类排名3044/3824；成立以来收益295.1%。 风险提示：市场有风险，投资需 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-038 苏州近岸蛋白质科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 12 日 （二） 股东大会召开的地点：苏州市吴江区文苑路 88 号东恒盛国际大酒店五楼 姑苏厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 48 | | --- | --- | | 普通股股东人数 | 48 | | 2、出席会议的股东所持有的表决权数量 | 47,717,078 | | 普通股股东所持有表决权数量 | 47,717,078 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 68.3909 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.3909 | （四） 表 ...

国浩律师（上海）事务所 关 于 苏州近岸蛋白质科技股份有限公司 2025 年第一次临时股东大会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 9 月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 致：苏州近岸蛋白质科技股份有限公司 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会于 2025 年 9 月 12 日召开。国浩律师（上海）事务所（以下简称"本 所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第一次临时股东 大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）等法律、法规及《上市公司股东会 ...

Core Viewpoint - The report outlines the continuous supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. after its IPO on the Sci-Tech Innovation Board, emphasizing the company's adherence to regulations and its operational performance despite financial losses. Continuous Supervision Work - The sponsor has established a robust continuous supervision system and work plan for the company, ensuring compliance with relevant regulations and effective communication [1][2] - The sponsor conducted regular visits, due diligence, and checks to monitor the company's operations and compliance with laws and regulations [1][2] - Throughout the supervision period, the company did not encounter any violations or breaches of commitments that required public disclosure [1][2] Financial Performance - For the first half of 2025, the company reported revenue of approximately 72.09 million, a year-on-year increase of 20.85% [8] - The net loss attributable to shareholders was approximately 24.22 million, with a net profit excluding non-recurring items of about -26.68 million [8] - The company’s cash flow from operating activities was -14.08 million, indicating a significant decline compared to the previous year [8] Core Competitiveness - The company has developed seven comprehensive technology platforms and 23 core technologies, which are crucial for maintaining its market competitiveness [5][9] - The company emphasizes the importance of protecting its core technologies to prevent leakage, which could adversely affect its operations [5][9] - A skilled and stable technical team is essential for sustaining technological leadership and core competitiveness [5][9] Industry Risks - The RNA vaccine and drug industry is still maturing, with uncertainties in demand for mRNA raw materials and reagents in various applications [7][8] - The company faces intense competition from both domestic and international players, which could impact its market position and profitability [6][7] Research and Development - The company invested approximately 26.1 million in R&D in the first half of 2025, accounting for 36.21% of its revenue, reflecting a slight decrease from the previous year [16] - As of June 30, 2025, the company holds 38 invention patents, 22 utility model patents, and 18 software copyrights, indicating a strong focus on innovation [16] Use of Raised Funds - The company raised approximately 186.30 million through its IPO, with 174.22 million remaining after deducting issuance costs, and has complied with regulations regarding the use of these funds [17][18]

民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 2025 年半年度持续督导跟踪报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试行）》 等有关法律法规和规范性文件的要求，负责近岸蛋白上市后的持续督导工作，并 出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 本持续督导期间，保荐机构已建立健全 | | 1 | 度，并针对具体的持续督导工作制定相 | 并有效执行了持续督导制度，并制定了 | | | 应的工作计划 | 相应的工作计划 | | | 根据中国证监会相关规定，在持续督导 | 本持续督导期间，保荐机构已与近岸蛋 | | | 工作开始前，与上市公司或相关当事人 | | | 2 | 签署持续督导协议，明确双方在持续督 | 白签订承销及保荐协议，该协议明确了 | ...

Core Viewpoint - The company is convening its first extraordinary general meeting of shareholders in 2025 to discuss key proposals, including the use of excess raised funds to supplement working capital and the reappointment of an accounting firm for financial auditing [6][8]. Group 1: Meeting Procedures - The meeting will follow a structured agenda, allowing shareholders to exercise their rights, including speaking, questioning, and voting [2][3]. - Shareholders must register and present necessary identification documents to participate in the meeting [1][2]. - Voting will be conducted through both on-site and online methods, with specific time frames for each [4][6]. Group 2: Proposals - Proposal 1 involves using CNY 72 million (approximately USD 10.1 million) of excess raised funds to permanently supplement working capital, which represents 29.73% of the total excess funds raised of CNY 242.2 million (approximately USD 34.1 million) [6][8]. - Proposal 2 seeks to reappoint Rongcheng Accounting Firm for the 2025 financial audit, with an audit fee of CNY 700,000 (approximately USD 98,000), maintaining the same fee as the previous year [8][12].